» Articles » PMID: 11742277

Selective Modulation of Chemokinesis, Degranulation, and Apoptosis in Eosinophils Through the PGD2 Receptors CRTH2 and DP

Overview
Date 2001 Dec 14
PMID 11742277
Citations 63
Authors
Affiliations
Soon will be listed here.
Abstract

Background: PGD(2) is the major prostanoid released by mast cells during an allergic response. Its role in the allergic response, however, remains unclear.

Objective: Because the accumulation of eosinophils is a feature of allergic reactions, we investigated the role of PGD(2) in the modulation of eosinophil function.

Methods: Circulating human eosinophils were isolated and challenged with PGD(2). The effects of PGD(2) on various eosinophil functions were then analyzed.

Results: PGD(2) binds with high affinity preferentially to 2 receptors, DP and chemoattractant receptor-homologous molecule expressed on T(H)2 cells (CRTH2). We show that both DP and CRTH2 are detectable on circulating eosinophils. We demonstrate that PGD(2) (1-10 nmol/L) induces a rapid change in human eosinophil morphology and an increase in chemokinesis and promotes eosinophil degranulation. These effects are induced by the CRTH2-selective agonist 13-14-dihydro-15-keto-PGD(2) (DK-PGD(2)) but not by the DP-selective agonist BW245C. These results suggest a role for CRTH2 in the modulation of eosinophil movement and in triggering the release of cytotoxic proteins. Finally, we demonstrate that BW245C, but not DK-PGD(2), can delay the onset of apoptosis in cultured eosinophils, presumably through interaction with DP.

Conclusion: These data support the hypothesis that PGD(2) controls eosinophil functions through 2 pharmacologically distinct receptors with independent functions. Blockade of PGD(2)-mediated effects on human eosinophils may reduce the damage caused by these cells during an allergic response, but inhibition of both receptors may be required.

Citing Articles

Molecular basis of lipid and ligand regulation of prostaglandin receptor DP2.

Xu J, Xu Y, Hou L, He X, Li Y, Zhao J Proc Natl Acad Sci U S A. 2024; 121(51):e2403304121.

PMID: 39665758 PMC: 11665870. DOI: 10.1073/pnas.2403304121.


Nonsteroidal antiinflammatory drug-exacerbated respiratory disease: molecular mechanism, management and treatment.

Ley-Tomas J, Xicotencatl-Tellez A, Garcia-Cruz M, Jimenez-Chobillon M Front Allergy. 2024; 5:1462985.

PMID: 39665076 PMC: 11631927. DOI: 10.3389/falgy.2024.1462985.


Phospholipid scramblase-1 regulates innate type 2 inflammation in mouse lungs via CRTH2-dependent mechanisms.

Hernandez-Gutierrez A, Majid S, Eberle A, Choi A, Sorkhdini P, Yang D J Clin Invest. 2023; 133(15).

PMID: 37289545 PMC: 10378191. DOI: 10.1172/JCI169583.


The randomized, single- and multiple- ascending dose studies of the safety, tolerability, pharmacokinetics of CSPCHA115 in healthy Chinese subjects.

Jing S, Liu W, Yang K, Lin Y, Yao X, Sun G Clin Transl Sci. 2022; 16(3):447-458.

PMID: 36495036 PMC: 10014699. DOI: 10.1111/cts.13455.


Anti-inflammatory effects of the prostaglandin D/prostaglandin DP1 receptor and lipocalin-type prostaglandin D synthase/prostaglandin D pathways in bacteria-induced bovine endometrial tissue.

Wu J, Bai F, Mao W, Liu B, Yang X, Zhang J Vet Res. 2022; 53(1):98.

PMID: 36435808 PMC: 9701374. DOI: 10.1186/s13567-022-01100-6.